Related Experiment Video

Updated: May 20, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Conjugated hyperbilirubinemia in children

David Brumbaugh1, Cara Mack

  • 1Digestive Health Institute, Children's Hospital of Colorado, University of Colorado Anschutz Medical Campus, Denver, CO, USA.

Pediatrics in Review
|July 4, 2012
PubMed

Insights

Persistent jaundice in newborns may indicate conjugated hyperbilirubinemia, a condition often caused by biliary atresia. Early recognition by 2-4 weeks is vital for prompt diagnosis and treatment in infants.

Area of Science:

  • Pediatrics
  • Neonatology
  • Hepatology

Background:

  • Conjugated hyperbilirubinemia can stem from diverse conditions including anatomic, infectious, autoimmune, and metabolic diseases.
  • While occurring throughout childhood, it is most frequently observed in the neonatal period.
  • Persistent jaundice in newborns necessitates a high index of suspicion for cholestasis.

Purpose of the Study:

  • To emphasize the critical importance of early recognition of conjugated hyperbilirubinemia in neonates.
  • To facilitate timely diagnosis and management of neonatal cholestasis, particularly biliary atresia.

Main Methods:

  • Clinical observation and diagnosis of neonatal cholestasis.
  • Monitoring for conjugated hyperbilirubinemia development between 2 and 4 weeks of age.

Main Results:

  • Biliary atresia is identified as the most common cause of neonatal cholestasis.
  • Prompt identification of conjugated hyperbilirubinemia aids in managing infants with biliary atresia.

Conclusions:

  • Early detection of conjugated hyperbilirubinemia (2-4 weeks post-birth) is crucial for infants.
  • Timely intervention improves outcomes for neonates with conditions like biliary atresia.

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...